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Introduction 
 
The lifetime risk of developing breast cancer is 1 in 8 for women in the 
Netherlands. Survival is good and improving, measuring quality of care 
in the various hospitals is complex. In the past, different definitions and 
scoring systems were used. Clinical audits provide an important tool for 
quality assessment using a uniform registration of all patients diagnosed 
with a certain disease.  
Material and methods 
 
The multidisciplinary national NABON Breast Cancer Audit (NBCA) started 
collecting data of all Dutch hospitals in 2011, facilitated by Comprehensive 
Cancer Centre the Netherlands (IKNL) and the Dutch Institute for Clinical 
Auditing (DICA). All aspects of breast cancer care are registered including 
diagnostics and different treatment modalities.  
 
The aim is to evaluate quality of care provided (2011 – 2013) 
 
Results 
 
All Dutch hospitals (n=92) participated by providing the data regarding 
delivered breast cancer care resulting in a database of more than 42.000 
breast cancer patients (5.745 DCIS and 36.396 invasive carcinomas) in 
three years time. Eighty-nine percent of invasive breast cancer patients 
were treated with primary surgery of which 62% (n=19.885) with breast 
conserving surgery. 30 quality indicators have been developed, 
representing the various disciplines involved in breast cancer care. 
Conclusions 
 
§  The continuous cycle of registration and providing feedback by clinical 
auditing provides a powerful tool for quality monitoring and improving breast 
cancer care.  
§  Quality of monodisciplinairy surgical and pathological aspects of care has 
improved over the years   
§  More complicated multidisciplinary issues like the use of primary systemic 
treatment and immediate reconstruction shows (unexplained) variation and 
detailed analyses of the variation between hospitals is needed to further 
improve these aspects of breast cancer care. 
Within three years time, several quality assessments are improved such as 
guideline compliance for pre- and postoperative multidisciplinary team 
(MDT) meetings, percentage of patients starting surgery within five weeks, 
percentage of patients with tumor positive margins after first breast 
conserving surgery for invasive breast cancer (see table). Pre-operative 
MDT meeting is shown in figure 2. In 2013, 2 hospitals are performing 
significantly below the national standard of 90%; these have their MDT 
meetings regularly, however, a digital report is not used. All hospitals 
performed below the national standard of 15% for the outcome indicator 
tumor positive margins (figure 3). The percentage of patients receiving an 
immediate reconstruction after ablative surgery (18%; 95% CI 0 – 73%) 
remained low with a large variation between hospitals figure 4.  
Table displaying various quality indicators of the NBCA 1 
Core values of the NBCA 
 
§  Initiated and managed by clinicians 
§  One nation-wide system 
§  Weekly updated benchmarked feedback 
§  Nation-wide evaluation of quality parameters 
§  Identify causes of variation 
§  Start quality improvement programs  
Number of patients per hospital (2012) Number of patients per hospital (2013) 
Quality indicator 2011 2013 
Pre-operative Multidisciplinary team meeting 81%	   96%	  
Postoperative Multidisciplinary team meeting 90%	   98%	  
Time to operation ≤ 5 weeks  
(immediate reconstruction after mastectomy excluded)  
80%	   85%	  
Tumor positive margins invasive breast cancer  
(without primary systemic treatment)	  
6.1%	   5.0%	  
Tumor positive margins DCIS 	   25%	   20%	  
Pre-operative systemic treatment for invasive breast cancer 	   10%	   12%	  
Immediate reconstruction after ablative surgery for invasive 
breast cancer	  
15%	   18%	  
Immediate reconstruction after ablative surgery for DCIS	   39%	   44%	   Number of patients per hospital (2011) 
Number of patients with breast conserving surgery 
without neo-adjuvant therapy for invasive breast  
cancer per hospital (2013) 
2 3 Tumor positive margins – invasive breast cancer Quality improvement of pre-operative MDT meeting for 2011, 2012, 2013 
Number of patients with mastectomy for 
invasive breast cancer per hospital (2013)  
Mastectomy with immediate reconstruction 4 
Hospital 
Standard 90% 
95% CI 
Mean 
Hospital 
Standard 90% 
95% CI 
Mean 
Hospital 
Standard 90% 
95% CI 
Mean 
Hospital 
Standard 15% 
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Mean 
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Mean 
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